{"id":73994,"date":"2025-01-29T15:51:33","date_gmt":"2025-01-29T13:51:33","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=lay_language&#038;p=73994"},"modified":"2025-01-29T15:51:34","modified_gmt":"2025-01-29T13:51:34","slug":"a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants","status":"publish","type":"lay_language","link":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/","title":{"rendered":"A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":11,"template":"","lay_language_category":[],"class_list":["post-73994","lay_language","type-lay_language","status-publish","has-post-thumbnail","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants - Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T13:51:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/29154430\/Image1-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1949\" \/>\n\t<meta property=\"og:image:height\" content=\"1118\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/\",\"url\":\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/\",\"name\":\"A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants - Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/29154430\/Image1-2.png\",\"datePublished\":\"2025-01-29T13:51:33+00:00\",\"dateModified\":\"2025-01-29T13:51:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/29154430\/Image1-2.png\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/29154430\/Image1-2.png\",\"width\":1949,\"height\":1118},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/#website\",\"url\":\"https:\/\/www.ipsen.com\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants - Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/","og_locale":"en_US","og_type":"article","og_title":"A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants - Global","og_url":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/","og_site_name":"Global","article_modified_time":"2025-01-29T13:51:34+00:00","og_image":[{"width":1949,"height":1118,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/29154430\/Image1-2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/","url":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/","name":"A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants - Global","isPartOf":{"@id":"https:\/\/www.ipsen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/29154430\/Image1-2.png","datePublished":"2025-01-29T13:51:33+00:00","dateModified":"2025-01-29T13:51:34+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/29154430\/Image1-2.png","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/29154430\/Image1-2.png","width":1949,"height":1118},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/lay-language\/a-phase-1-open-label-repeat-dose-study-to-assess-the-pharmacokinetics-safety-and-tolerability-following-administration-of-elafibranor-in-healthy-japanese-and-non-asian-participants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/"},{"@type":"ListItem","position":2,"name":"A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/#website","url":"https:\/\/www.ipsen.com\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/lay_language\/73994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/lay_language"}],"about":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/types\/lay_language"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/users\/11"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/lay_language\/73994\/revisions"}],"predecessor-version":[{"id":73995,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/lay_language\/73994\/revisions\/73995"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/media\/73990"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/media?parent=73994"}],"wp:term":[{"taxonomy":"lay_language_category","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/lay_language_category?post=73994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}